Nancy McKinstry - 24 Apr 2026 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Reporting relationship: Director
Issuer ticker: ABT
Reported as of: 24 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Apr 2026, 19:02:40 UTC
Prior SEC filing: 17 Feb 2026
Next SEC filing: 19 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Nancy McKinstry by Jessica H. Paik, Attorney-in-Fact

Key filing fact

Nancy McKinstry filed Form 4 for ABBOTT LABORATORIES (ABT) on 28 Apr 2026.

Key facts

This page summarizes Nancy McKinstry's Form 4 filing for ABBOTT LABORATORIES (ABT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 28 Apr 2026, 19:02.

Change

Previous filing in this sequence was filed on 17 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001294731 Primary reporting owner

McKinstry Nancy

Relationship: Director
Address: 100 ABBOTT PARK ROAD, ABBOTT PARK
Signature: /s/ Nancy McKinstry by Jessica H. Paik, Attorney-in-Fact
Signature date: 28 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ABT transaction

Common shares without par value

Award

Transaction value
Shares: +2,286
Change %: +5.9%
Price: $0.000000^*
Shares after: 41,010
Date: 24 Apr 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ABT transaction Derivative

Option (right to buy)

Award

Transaction value
Shares: +2,305
Change %
Price: $0.000000^*
Shares after: 2,305
Date: 24 Apr 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 2,305
Exercise price: $91.86
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

Footnote F2

Stock option granted under the Program, in a transaction exempt from Section 16 under Rule 16b-3.